Skip to main content
. 2021 Oct 29;64(21):16159–16176. doi: 10.1021/acs.jmedchem.1c01437

Table 5. Antileishmanial Activity of Compounds 22–31.

graphic file with name jm1c01437_0011.jpg

          MRC5a
HLM HamLM
compound R1 R2 intramacrophage L. infantum amastigote EC50 (μM)a PMMa CC50 (μM) CC50 (μM) SIb Clint (μL/min/mg)
22 H 2-pyridyl 1.7 >64 44.8 30 <11.9 18
23 CH3 2-pyridyl 1.8 >64 >64 >39 <11.9 <11.9
24 CH3 phenyl 37 >64 >64 >1.7 <11.9 n.d.
25 CH3 2-pyridyl-6-OMe 0.8 32 >64 >80 23 40
26 CH3 2-pyridyl-6-Me 6.4 >64 >64 >10 n.d. n.d.
27 CH3 3-pyridyl 38 >64 >64 >1.8 n.d. n.d.
28 CH3 2-pyridyl 0.5 49 18 37 <11.9 40
29 CH3 2-pyridyl 1.7 29 45 18 <11.9 82
30 CH3 2-pyridyl 0.6 32 2.3 4 <11.9 88
31   2-pyridyl 2.0 >64 >64 >32 19 12
a

Geometric mean value of at least two independent tests.

b

Selectivity index representing the ratio of CC50/EC50; data are presented as the geometric mean value of ratios calculated using separate data from at least two independent tests. n.d., not determined.